Jiang M, Ding H, Huang Y, Cheng C, Lau C, Xia Y, et al. Thioridazine protects against disturbed flow-induced atherosclerosis by inhibiting RhoA/YAP-mediated endothelial inflammation. Acta Pharmacol Sin. 2023;44:1977-1988 pubmed publisher

Ding H, Jiang M, Lau C, Luo J, Chan A, Wang L, et al. Curaxin CBL0137 inhibits endothelial inflammation and atherogenesis via suppression of the Src-YAP signalling axis. Br J Pharmacol. 2022;: pubmed publisher

Tsai J, Cejas P, Wang D, Patel S, Wu D, Arounleut P, et al. FOXR2 is an epigenetically regulated pan-cancer oncogene that activates ETS transcriptional circuits. Cancer Res. 2022;: pubmed publisher

Dubois F, Shapira O, Greenwald N, Zack T, Wala J, Tsai J, et al. Structural variants shape driver combinations and outcomes in pediatric high-grade glioma. Nat Cancer. 2022;3:994-1011 pubmed publisher

Tanton H, Sewastianik T, Seo H, Remillard D, Pierre R, Bala P, et al. A novel β-catenin/BCL9 complex inhibitor blocks oncogenic Wnt signaling and disrupts cholesterol homeostasis in colorectal cancer. Sci Adv. 2022;8:eabm3108 pubmed publisher

Giacomelli A, Yang X, Lintner R, McFarland J, Duby M, Kim J, et al. Mutational processes shape the landscape of TP53 mutations in human cancer. Nat Genet. 2018;50:1381-1387 pubmed publisher